W
William W. Busse
Researcher at University of Wisconsin-Madison
Publications - 740
Citations - 62685
William W. Busse is an academic researcher from University of Wisconsin-Madison. The author has contributed to research in topics: Asthma & Eosinophil. The author has an hindex of 115, co-authored 697 publications receiving 56703 citations. Previous affiliations of William W. Busse include National Institutes of Health & University at Buffalo.
Papers
More filters
Journal ArticleDOI
Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity
Stanley J. Szefler,Thomas B. Casale,Tmirah Haselkorn,Bongin Yoo,Benjamin Ortiz,Meyer Kattan,William W. Busse +6 more
TL;DR: Omalizumab reduces exacerbations in children with moderate-to-severe persistent allergic asthma, and may provide greater benefit in childrenWith more severe asthma subtypes.
Journal ArticleDOI
Greater Treatment Benefit with Omalizumab in Children with Increased Asthma Severity: Exploratory Analyses from the Inner-City Anti-IgE Therapy for Asthma (ICATA) Study
William W. Busse,Tmirah Haselkorn,Karin Rosén,Benjamin Trzaskoma,Benjamin Ortiz,Stanley J. Szefler +5 more
Proceedings ArticleDOI
Consistently Favorable Safety Profile Of Fluticasone Furoate (FF), A Once-Daily (OD) Inhaled Corticosteroid (ICS), Across A Range Of Treatment Steps In Patients With Uncontrolled Asthma
Eugene R. Bleecker,Eric D. Bateman,William W. Busse,Jan Lötvall,Ashley Woodcock,Lucy Frith,Loretta Jacques,Hilary Medley,Brett Haumann +8 more
Journal ArticleDOI
Exercise‐induced anaphylaxis
TL;DR: These cases represent additional evidence that exercise‐induced anaphylaxis is not rare but can be misdiagnosed in some patients, and the characteristics of this response are reviewed.
Journal ArticleDOI
Expression of corticosteroid-regulated genes by PBMCs in children with asthma.
Elena Goleva,Denise C. Babineau,Michelle A. Gill,Leisa P. Jackson,Baomei Shao,Zheng Hu,Andrew H. Liu,Cynthia M. Visness,Christine A. Sorkness,Donald Y.M. Leung,Alkis Togias,William W. Busse +11 more
TL;DR: PBMCs of children with difficult‐to‐control asthma treated with guidelines‐based therapy and requiring high‐dose ICSs had reduced in vitro responsiveness to corticosteroids.